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Abstract 
Objectives: oxidative stress is suggested to play an im-
portant  role  in  the  pathogenesis  of  nonalcoholic
steatohepatitis (nasH). the present study was aimed
to compare plasma levels of antioxidants in patients
suffering from nasH and healthy controls. 
Methods:  Plasma  levels  of  the  antioxidants  α-toco-
pherol, γ-tocopherol, lutein, zeaxanthin, β-cryptoxan-
thin,  lycopene,  α-carotene  β-carotene  were  deter-
mined in 57 patients with biopsy-proven nasH and
40 healthy controls. 
Results: levels of α-tocopherol (22.4 vs. 26.8 nmol/
ml; p<0.01), lutein (0.19 vs. 0.33 nmol/ml; p<0.0001),
zeaxanthin (0.04 vs. 0.08 nmol/ml; p<0.0001), lyco  -
pene (0.15 vs. 0.42 nmol/ml; p<0.0001), α-carotene
(0.03  vs.  0.06  nmol/ml;  p<0.005)  and  β-carotene 
(0.25 vs. 0.39 nmol/ml; p<0.01) were significantly de-
creased in nasH patients compared to controls. age,
aminotransferase status (alt, ast) and BMI were not
correlated  with  the  levels  of  tocopherols  or  caro  -
tenoids. 
Conclusions: Given the decreased levels supplementa-
tion  of  lipophilic  antioxidants  might  be  a  rational
treatment option for patients with nasH.
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IntRodUCtIon
nonalcoholic steatohepatitis (nasH) is a disease with
a prevalence of 3-6% in the general population and up
to 50% among patients with obesity [1]. nasH may
progress to cirrhosis in a substantial number of pa-
tients.  due  to  the  lack  of  an  established  treatment
there is an increasing need for better understanding
the pathogenesis of nasH in order to develop effec-
tive treatment options.
Insulin  resistance  and  oxidative  stress  have  been
suggested to be major factors for the development of
steatosis and progression to steatohepatitis [1]. In the
processes of fatty acid oxidation and oxidative phos-
phorylation, peroxisomes and mitochondria leak reac-
tive oxygen species (Ros) damaging biologically im-
portant molecules and cellular structures [1]. due to
its  metabolic  activity,  the  liver  is  exposed  to  a  high
load of pro-oxidants which are scavenged by an an-
tioxidant network including dietary antioxidants. sup-
plementation of antioxidants was therefore proposed
to  counteract  elevated  Ros  levels  due  to  increased
production  and  impaired  inactivation.  among  the
promising antioxidant compounds are several micro  -
nutrients including tocopherols and carotenoids [2, 3]. 
despite the theoretical and practical rationale for a
supplementation with lipophilic antioxidants, levels of
tocopherols and carotenoids and have not been sys-
temically analyzed in patients with nasH. decreased
levels of antioxidants have been described in other liv-
er diseases like alcoholic hepatitis, chronic hepatitis C,
hemochromatosis and wilson`s disease [4]. the pre-
sent study was aimed to compare plasma levels of to-
copherols and carotenoids in patients suffering from
nasH and healthy controls. 
PatIEnts, MEtHods and statIstICs
fifty  seven  consecutive  patients  with  biopsy-proven
nasH were included in the study. seven of the 57 pa-
tients took vitamin E or multivitamin supplements at
the time of blood sampling and were assessed seper-
ately. Exclusion criteria were other concomitant liver
diseases, alcohol consumption >20 g/day or a choles-
terol  level  >350  mg/dl.  forty  healthy  employees
served as controls. the study has been approved by
the local ethical committee and all subjects gave in-
formed consent to the work. nasH was histologically
assessed according to Brunt et al. [5]. liver biopsy was
obtained at no more than 12 months apart from blood
sampling.  Plasma  levels  of  α-tocopherol,  γ-toco-
pherol, retinol, lutein, zeaxanthin, β-cryptoxanthin, ly-
copene, α-carotene and β-carotene were determined
by means of HPlC following an established protocol
[6]. statistics: two sided t-test and descriptive statistics
were used to weight analyses for means with the sPss
18.0  statistical  software.  significance  was  set  at  the
p<0.05 level.
REsUlts
Clinical and laboratory data are summarized in table
1. α-tocopherol, lutein, lycopene, α- and β-carotene
were significantly decreased in nasH patients com-
pared  to  healthy  controls:  plasma  levels  of  α-toco-
pherol were lowered by 16% and levels of carotenoids
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7) Erhardt_Umbruchvorlage  14.02.11  14:29  Seite 76by  31-64%.  Patients  with  nasH  displayed  higher
serum levels of ferritin but similar transferrrin satura-
tion compared to healthy controls. nasH patients us-
ing vitamin supplements had higher α-tocopherol and
β-carotene levels than those which did not apply addi-
tional vitamins (table 1). BMI, alt, ast, GGt and
cholesterol levels were not correlated to the levels of
tocopherols  or  carotenoids.  Hba1c  was  significantly
correlated to ferritin (r=0.439; p<0.002) but not to the
levels  of  carotenes  or  tocopherols.  age  showed  a
moderate  correlation  to  α-tocopherol  (r  =  0.395;
p<0.05) but not to γ-tocopherol or carotenes. there
was a weak inverse correlation of γ-tocopherol to the
grade of inflammation (r = -0,545; p<0.07) and stage
of fibrosis (r = -0.388; p<0.01). 
dIsCUssIon
the present study demonstrates that dietary antioxi-
dant compounds are significantly decreased in patients
with nasH compared to healthy controls. the rea-
sons for this observation might be a depletion of an-
tioxidants in order to counterbalance oxidative stress.
low levels of antioxidants might also be caused by a
reduced oral uptake. the present finding of decreased
antioxidants  in  patients  with  nasH  could  argue  in
favour of an antioxidant treatment strategy.
However, data on the supplementation with antioxi-
dants in nasH are not conclusive and based only on
small trials. Most studies investigated vitamin E substi-
tution  but  no  prospective  study  regarding  treatment
with carotenoids has been launched. In a pilot study
with 11 children with nasH, elevated blood amino-
transferases activity was decreased upon vitamin E in-
tervention [7] and in  a small randomized controlled
trial the combination of ursodeoxycholic acid with vit-
amin E improved alt levels as well as the inflamma-
tory activity in the liver. a therapy of vitamins E and
C for 6 months improved liver fibrosis in 45 patients
in a placebo-controlled trial [2] but had no effect on
transaminases  and  necroinflamatory  activity.  a  12
week therapy with vitamin E in 16 adults provided no
additional benefit to that obtained by lifestyle modifi-
cations [8], whereas a longer treatment of 12 months
showed improvements in inflammation and fibrosis in
a small, nonrandomized study [9]. discrepancies in the
studies might derive from the use of different vitamin
E compounds, dosages and treatment durations. the
term vitamin E summarizes structurally different toco-
pherols and tocotrienols, four of each group, which
naturally occur as only one optical isomer [10]. syn-
thetic vitamin E, mainly α-tocopherol, usually occurs
as a mixture of various optical isomers. RRR-α-toco-
pherol is the biologically most active vitamin and is se-
lected in the liver by the α-tocopherol-transfer-protein
(α-ttP).  differences  in  the  vitamin  pattern  of  the
supplements may explain the divergent results of the
intervention  studies.  furthermore,  tocopherols  and
carotenoids  exert  additional  non-oxidative  functions
like immuno-modulation, regulation of cell cycle and
induction of detoxifying enzymes involved in mecha-
nisms  of  cell  protection  [10].  However  the  so  far
largest  and  most  recent  randomized,  double-blind,
placebo-controlled  trial  of  247  patients  who  had
nasH but not diabetes showed that vitamin E given
as  RRR-α-tocopherol  at  a  dose  800  IU/day  for  96
weeks improved key histological features and liver en-
zymes [11].
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Table 1. Baseline characteristics of healthy controls (n=40) and patients with nasH without (n = 50) and with vitamin supple-
mentation (n = 7).
Healthy  nasH P value nasH P- value
controls (n = 50) (different  + vitamin  (different 
(n = 40) from control) supplements from nasH)
(n = 7)
α-tocopherol [nmol/ml] 26.8 ﾱ 7.9 22.4ﾱ 8.1 0.01 39.6 ﾱ 1.5 0.0001
γ-tocopherol [nmol/ml] 2.5 ﾱ 0.8 2.5 ﾱ 0.9 n.s. 3.0 ﾱ 1.0 n.s. 
Retinol [nmol/ml] 1.5 ﾱ 1.9 1.2 ﾱ 0.5 n.s. 1.3 ﾱ 0.4 n.s.
lutein [nmol/ml] 0.33 ﾱ 0.11 0.19 ﾱ 0.09 0.0001 0.26 ﾱ 0.17 n.s.
Zeaxanthin [nmol/ml] 0.08 ﾱ 0.03 0.04 ﾱ 0.01 0.0001 0.045 ﾱ 0.03 n.s.
Cryptoxanthin [nmol/ml] 0.13 ﾱ 0.07 0.09 ﾱ 0.09 n.s. (0.06) 0.12 ﾱ 0.06 n.s.
lycopene [nmol/ml] 0.42 ﾱ 0.24 0.15 ﾱ 0.16  0.001 0.50 ﾱ 0.37 n.s. (0.07)
α-Carotene [nmol/ml] 0.06 ﾱ 0.05 0.03 ﾱ 0.03 0.005 0.07 ﾱ 0.09 n.s.
β-Carotene [nmol/ml] 0.39 ﾱ 0.26 0.25 ﾱ 0.26 0.01 0.42 ﾱ 0.27 0.03
ferritin [ﾵg/l] 96 ﾱ 73 237 ﾱ 293 0.007 103 ﾱ 99 n.s.
ts [%] 31 ﾱ 13 34 ﾱ 13 n.s. 34 ﾱ 11 n.s.
age [years] 50 ﾱ 15 51 ﾱ 16 n.s. 49 ﾱ 10 n.s.
Gender [% males] 54 55 n.s. 57 n.s.
abbr.: ts = transferrin saturation
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lycopene  is  a  predominant  carotenoid  in  human
plasma and considered to be a potent antioxidant and
a singlet oxygen quencher [12]. there is increasing evi-
dence in support for a protective role of lycopene in a
variety  of  human  diseases  with  increased  oxidative
stress including cancers, cardiovascular disorders, os-
teoporosis and male infertility [12]. lycopene was sig-
nificantly  reduced  in  nasH  patients  of  the  present
study. so far there are no randomized studies that have
investigated  the  role  of  lycopene  in  patients  with
nasH.  However,  the  possibility  for  an  easy  dietary
supplementation makes lycopene an interesting candi-
date for the treatment of nasH. 
In conclusion, the observed decrease of tocopherol
and carotenoid levels implies that oxidative stress plays
a role in the pathogenesis of nasH. the present data
support the study by sanyal et al. that antioxidant sup-
plementation might be a rational treatment option for
patients with nasH. However, delineation of treat-
ment  strategies  in  nasH  will  have  to  take  into  ac-
count  suitable  treatment  durations  and  clinical  end-
points, the use of naturally occuring tocopherols and
the risk of pro-oxidative effects of some carotenoids. 
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